#BEGIN_DRUGCARD DB05260

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Ganite

# CAS_Registry_Number:
13494-90-1

# ChEBI_ID:
Not Available

# Chemical_Formula:
GaN3O9

# Chemical_IUPAC_Name:
gallium(3+) ion tris(nitrooxidane)

# Chemical_Structure:
Not Available

# Creation_Date:
2007-11-18 11:22:52 -0700

# DPD_Drug_ID_Number:
Not Available

# Description:
Gallium nitrate is a drug that is used to treat hyper-calcemia, or too much calcium in the blood. This condition may occur when individuals develop various types of cancer. Gallium nitrate is also known by the common brand name Ganite.

# Dosage_Forms:
Not Available

# Drug_Category:
Antineoplastic Agents

# Drug_Interactions:
Vancomycin	Additive nephrotoxic effects may occur. Avoid concomitant therapy.

# Drug_Reference:
15605917	Leyland-Jones B: Treating cancer-related hypercalcemia with gallium nitrate. J Support Oncol. 2004 Nov-Dec;2(6):509-16.
15651176	Chitambar CR: Apoptotic mechanisms of gallium nitrate: basic and clinical investigations. Oncology (Williston Park). 2004 Nov;18(13 Suppl 10):39-44.
16613662	Cvitkovic F, Armand JP, Tubiana-Hulin M, Rossi JF, Warrell RP Jr: Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. Cancer J. 2006 Jan-Feb;12(1):47-53.
17308060	Yang M, Kroft SH, Chitambar CR: Gene expression analysis of gallium-resistant and gallium-sensitive lymphoma cells reveals a role for metal-responsive transcription factor-1, metallothionein-2A, and zinc transporter-1 in modulating the antineoplastic activity of gallium nitrate. Mol Cancer Ther. 2007 Feb;6(2):633-43.

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Gallium nitrate

# HET_ID:
Not Available

# Half_Life:
Alpha: 1 hour. Beta: 24 hours, but lengthens to 72 to 115 hours with prolonged intravenous infusion.

# InChI_Identifier:
InChI=1S/Ga.3NO3/c;3*2-1(3)4/q+3;3*-1

# InChI_Key:
InChIKey=CHPZKNULDCNCBW-UHFFFAOYSA-N

# Indication:
For the treatment of hypercalcemia. Also intended for the treatment of non-hodgkin's lymphoma.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
5261

# Mechanism_Of_Action:
Gallium nitrate is believed to exert a hypocalcemic effect by inhibiting calcium resorption from bone. Gallium nitrate localizes preferentially where bone resorption and remodeling is occurring, and inhibits osteoclast activity. Inhibition of resorption may occur via a reduction in increased bone turnover. It seems to enhance hydroxyapatite function, inhibit osteocalcin, and inhibit the vacuolar ATPase on the osteoclast ruffled membrane. All these aid in the reduction of bone resorption.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
255.738

# Molecular_Weight_Mono:
254.889034525

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164781198

# Pharmacology:
Gallium nitrate exerts hypocalcemic effect by inhibiting calcium resorption from bone, possibly by stabilizing bone matrix, thereby reducing increased bone turnover. Gallium nitrate inhibits the growth of various lymphoma cell lines in vitro and exhibits antitumor activity in patients with lymphoma. The mechanism(s) of cytotoxicity is (are) only partly understood but appears to involve a two-step process: (1) targeting of gallium to cells, and (2) acting on multiple, specific intracellular processes. Gallium shares certain chemical properties with iron; therefore, it binds avidly to the iron transport protein transferrin. Transferrin-gallium complexes preferentially target cells that express transferrin receptors on their surface. Expression of transferrin receptors is particularly high on lymphoma cells. Cellular uptake of the gallium-transferrin complex leads to inhibition of cellular proliferation primarily via disruption of iron transport and homeostasis and blockade of ribonucleotide reductase. Recent studies have shown that cellular uptake of gallium leads to activation of caspases and induction of apoptosis. In phase II trials in patients with relapsed or refractory lymphoma, the antitumor activity of gallium nitrate is similar to, or better than, that of other commonly used chemotherapeutic agents.

# Predicted_LogP_Hydrophobicity:
0

# Predicted_LogS:
0

# Predicted_Water_Solubility:
Not Available

# Primary_Accession_No:
DB05260

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
61635

# PubChem_Substance_ID:
46508923

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:24:02 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasm

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
12776257	Straus DJ: Gallium nitrate in the treatment of lymphoma. Semin Oncol. 2003 Apr;30(2 Suppl 5):25-33.
1335254	Narasimhan J, Antholine WE, Chitambar CR: Effect of gallium on the tyrosyl radical of the iron-dependent M2 subunit of ribonucleotide reductase. Biochem Pharmacol. 1992 Dec 15;44(12):2403-8.
15651176	Chitambar CR: Apoptotic mechanisms of gallium nitrate: basic and clinical investigations. Oncology (Williston Park). 2004 Nov;18(13 Suppl 10):39-44.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
RRM2

# Drug_Target_1_GenBank_ID_Gene:
X59618

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
RRM2

# Drug_Target_1_Gene_Sequence:
>1170 bp
ATGCTCTCCCTCCGTGTCCCGCTCGCGCCCATCACGGACCCGCAGCAGCTGCAGCTCTCG
CCGCTGAAGGGGCTCAGCTTGGTCGACAAGGAGAACACGCCGCCGGCCCTGAGCGGGACC
CGCGTCCTGGCCAGCAAGACCGCGAGGAGGATCTTCCAGGAGCCCACGGAGCCGAAAACT
AAAGCAGCTGCCCCCGGCGTGGAGGATGAGCCGCTGCTGAGAGAAAACCCCCGCCGCTTT
GTCATCTTCCCCATCGAGTACCATGATATCTGGCAGATGTATAAGAAGGCAGAGGCTTCC
TTTTGGACCGCCGAGGAGGTTGACCTCTCCAAGGACATTCAGCACTGGGAATCCCTGAAA
CCCGAGGAGAGATATTTTATATCCCATGTTCTGGCTTTCTTTGCAGCAAGCGATGGCATA
GTAAATGAAAACTTGGTGGAGCGATTTAGCCAAGAAGTTCAGATTACAGAAGCCCGCTGT
TTCTATGGCTTCCAAATTGCCATGGAAAACATACATTCTGAAATGTATAGTCTTCTTATT
GACACTTACATAAAAGATCCCAAAGAAAGGGAATTTCTCTTCAATGCCATTGAAACGATG
CCTTGTGTCAAGAAGAAGGCAGACTGGGCCTTGCGCTGGATTGGGGACAAAGAGGCTACC
TATGGTGAACGTGTTGTAGCCTTTGCTGCAGTGGAAGGCATTTTCTTTTCCGGTTCTTTT
GCGTCGATATTCTGGCTCAAGAAACGAGGACTGATGCCTGGCCTCACATTTTCTAATGAA
CTTATTAGCAGAGATGAGGGTTTACACTGTGATTTTGCTTGCCTGATGTTCAAACACCTG
GTACACAAACCATCGGAGGAGAGAGTAAGAGAAATAATTATCAATGCTGTTCGGATAGAA
CAGGAGTTCCTCACTGAGGCCTTGCCTGTGAAGCTCATTGGGATGAATTGCACTCTAATG
AAGCAATACATTGAGTTTGTGGCAGACAGACTTATGCTGGAACTGGGTTTTAGCAAGGTT
TTCAGAGTAGAGAACCCATTTGACTTTATGGAGAATATTTCACTGGAAGGAAAGACTAAC
TTCTTTGAGAAGAGAGTAGGCGAGTATCAGAGGATGGGAGTGATGTCAAGTCCAACAGAG
AATTCTTTTACCTTGGATGCTGACTTCTAA

# Drug_Target_1_General_Function:
Involved in oxidoreductase activity

# Drug_Target_1_General_References:
11978970	Zhou B, Yen Y: Characterization of the human ribonucleotide reductase M2 subunit gene; genomic structure and promoter analyses. Cytogenet Cell Genet. 2001;95(1-2):52-9.
1627826	Pavloff N, Rivard D, Masson S, Shen SH, Mes-Masson AM: Sequence analysis of the large and small subunits of human ribonucleotide reductase. DNA Seq. 1992;2(4):227-34.

# Drug_Target_1_HGNC_ID:
HGNC:10452

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
4218

# Drug_Target_1_Locus:
2p25-p24

# Drug_Target_1_Molecular_Weight:
44878

# Drug_Target_1_Name:
Ribonucleoside-diphosphate reductase M2 subunit

# Drug_Target_1_Number_of_Residues:
389

# Drug_Target_1_PDB_ID:
1H0N

# Drug_Target_1_Pathway:
Gemcitabine Pathway	SMP00446

# Drug_Target_1_Pfam_Domain_Function:
PF00268	Ribonuc_red_sm

# Drug_Target_1_Protein_Sequence:
>Ribonucleoside-diphosphate reductase M2 subunit
MLSLRVPLAPITDPQQLQLSPLKGLSLVDKENTPPALSGTRVLASKTARRIFQEPTEPKT
KAAAPGVEDEPLLRENPRRFVIFPIEYHDIWQMYKKAEASFWTAEEVDLSKDIQHWESLK
PEERYFISHVLAFFAASDGIVNENLVERFSQEVQITEARCFYGFQIAMENIHSEMYSLLI
DTYIKDPKEREFLFNAIETMPCVKKKADWALRWIGDKEATYGERVVAFAAVEGIFFSGSF
ASIFWLKKRGLMPGLTFSNELISRDEGLHCDFACLMFKHLVHKPSEERVREIIINAVRIE
QEFLTEALPVKLIGMNCTLMKQYIEFVADRLMLELGFSKVFRVENPFDFMENISLEGKTN
FFEKRVGEYQRMGVMSSPTENSFTLDADF

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides

# Drug_Target_1_SwissProt_ID:
P31350

# Drug_Target_1_SwissProt_Name:
RIR2_HUMAN

# Drug_Target_1_Synonyms:
EC 1.17.4.1
Ribonucleotide reductase small chain
Ribonucleotide reductase small subunit

# Drug_Target_1_Theoretical_pI:
5.05

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Endomembrane system

# Drug_Target_2_Chromosome_Location:
8

# Drug_Target_2_Drug_References:
12776254	Bockman R: The effects of gallium nitrate on bone resorption. Semin Oncol. 2003 Apr;30(2 Suppl 5):5-12.
15206110	Jakupec MA, Keppler BK: Gallium and other main group metal compounds as antitumor agents. Met Ions Biol Syst. 2004;42:425-62.
9144341	Mattsson JP, Skyman C, Palokangas H, Vaananen KH, Keeling DJ: Characterization and cellular distribution of the osteoclast ruffled membrane vacuolar H+-ATPase B-subunit using isoform-specific antibodies. J Bone Miner Res. 1997 May;12(5):753-60.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
M60346

# Drug_Target_2_GenBank_ID_Protein:
179563

# Drug_Target_2_GeneCard_ID:
ATP6V1B2

# Drug_Target_2_Gene_Name:
ATP6V1B2

# Drug_Target_2_Gene_Sequence:
Not Available

# Drug_Target_2_General_Function:
Energy production and conversion

# Drug_Target_2_General_References:
12643545	Basrur V, Yang F, Kushimoto T, Higashimoto Y, Yasumoto K, Valencia J, Muller J, Vieira WD, Watabe H, Shabanowitz J, Hearing VJ, Hunt DF, Appella E: Proteomic analysis of early melanosomes: identification of novel melanosomal proteins. J Proteome Res. 2003 Jan-Feb;2(1):69-79.
1373501	Nelson RD, Guo XL, Masood K, Brown D, Kalkbrenner M, Gluck S: Selectively amplified expression of an isoform of the vacuolar H(+)-ATPase 56-kilodalton subunit in renal intercalated cells. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3541-5.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
17081065	Chi A, Valencia JC, Hu ZZ, Watabe H, Yamaguchi H, Mangini NJ, Huang H, Canfield VA, Cheng KC, Yang F, Abe R, Yamagishi S, Shabanowitz J, Hearing VJ, Wu C, Appella E, Hunt DF: Proteomic and bioinformatic characterization of the biogenesis and function of melanosomes. J Proteome Res. 2006 Nov;5(11):3135-44.
2145275	Bernasconi P, Rausch T, Struve I, Morgan L, Taiz L: An mRNA from human brain encodes an isoform of the B subunit of the vacuolar H(+)-ATPase. J Biol Chem. 1990 Oct 15;265(29):17428-31.
7706273	Lee BS, Underhill DM, Crane MK, Gluck SL: Transcriptional regulation of the vacuolar H(+)-ATPase B2 subunit gene in differentiating THP-1 cells. J Biol Chem. 1995 Mar 31;270(13):7320-9.
7945239	van Hille B, Richener H, Schmid P, Puettner I, Green JR, Bilbe G: Heterogeneity of vacuolar H(+)-ATPase: differential expression of two human subunit B isoforms. Biochem J. 1994 Oct 1;303 ( Pt 1):191-8.

# Drug_Target_2_HGNC_ID:
GNC:854

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
6315

# Drug_Target_2_Locus:
8p22-p21

# Drug_Target_2_Molecular_Weight:
56500.2

# Drug_Target_2_Name:
V-type proton ATPase subunit B, brain isoform

# Drug_Target_2_Number_of_Residues:
511

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00006	ATP-synt_ab
PF00306	ATP-synt_ab_C
PF02874	ATP-synt_ab_N

# Drug_Target_2_Protein_Sequence:
>V-type proton ATPase subunit B, brain isoform
MALRAMRGIVNGAAPELPVPTGGPAVGAREQALAVSRNYLSQPRLTYKTVSGVNGPLVIL
DHVKFPRYAEIVHLTLPDGTKRSGQVLEVSGSKAVVQVFEGTSGIDAKKTSCEFTGDILR
TPVSEDMLGRVFNGSGKPIDRGPVVLAEDFLDIMGQPINPQCRIYPEEMIQTGISAIDGM
NSIARGQKIPIFSAAGLPHNEIAAQICRQAGLVKKSKDVVDYSEENFAIVFAAMGVNMET
ARFFKSDFEENGSMDNVCLFLNLANDPTIERIITPRLALTTAEFLAYQCEKHVLVILTDM
SSYAEALREVSAAREEVPGRRGFPGYMYTDLATIYERAGRVEGRNGSITQIPILTMPNDD
ITHPIPDLTGYITEGQIYVDRQLHNRQIYPPINVLPSLSRLMKSAIGEGMTRKDHADVSN
QLYACYAIGKDVQAMKAVVGEEALTSDDLLYLEFLQKFERNFIAQGPYENRTVFETLDIG
WQLLRIFPKEMLKRIPQSTLSEFYPRDSAKH

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Non-catalytic subunit of the peripheral V1 complex of vacuolar ATPase. V-ATPase is responsible for acidifying a variety of intracellular compartments in eukaryotic cells

# Drug_Target_2_SwissProt_ID:
P21281

# Drug_Target_2_SwissProt_Name:
VATB2_HUMAN

# Drug_Target_2_Synonyms:
Endomembrane proton pump 58 kDa subunit
HO57
V-ATPase subunit B 2
Vacuolar proton pump subunit B 2

# Drug_Target_2_Theoretical_pI:
5.55

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Secreted protein

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
8366144	Jenis LG, Waud CE, Stein GS, Lian JB, Baran DT: Effect of gallium nitrate in vitro and in normal rats. J Cell Biochem. 1993 Jul;52(3):330-6.
8381250	Guidon PT Jr, Salvatori R, Bockman RS: Gallium nitrate regulates rat osteoblast expression of osteocalcin protein and mRNA levels. J Bone Miner Res. 1993 Jan;8(1):103-12.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
BGLAP

# Drug_Target_3_GenBank_ID_Gene:
X53698

# Drug_Target_3_GenBank_ID_Protein:
36093

# Drug_Target_3_GeneCard_ID:
BGLAP

# Drug_Target_3_Gene_Name:
BGLAP

# Drug_Target_3_Gene_Sequence:
>303 bp
ATGAGAGCCCTCACACTCCTCGCCCTATTGGCCCTGGCCGCACTTTGCATCGCTGGCCAG
GCAGGTGCGAAGCCCAGCGGTGCAGAGTCCAGCAAAGGTGCAGCCTTTGTGTCCAAGCAG
GAGGGCAGCGAGGTAGTGAAGAGACCCAGGCGCTACCTGTATCAATGGCTGGGAGCCCCA
GTCCCCTACCCGGATCCCCTGGAGCCCAGGAGGGAGGTGTGTGAGCTCAATCCGGACTGT
GACGAGTTGGCTGACCACATCGGCTTTCAGGAGGCCTATCGGCGCTTCTACGGCCCGGTC
TAG

# Drug_Target_3_General_Function:
Involved in calcium ion binding

# Drug_Target_3_General_References:
2336375	Kiefer MC, Saphire AC, Bauer DM, Barr PJ: The cDNA and derived amino acid sequences of human and bovine bone Gla protein. Nucleic Acids Res. 1990 Apr 11;18(7):1909.
3019668	Celeste AJ, Rosen V, Buecker JL, Kriz R, Wang EA, Wozney JM: Isolation of the human gene for bone gla protein utilizing mouse and rat cDNA clones. EMBO J. 1986 Aug;5(8):1885-90.
6967872	Poser JW, Esch FS, Ling NC, Price PA: Isolation and sequence of the vitamin K-dependent protein from human bone. Undercarboxylation of the first glutamic acid residue. J Biol Chem. 1980 Sep 25;255(18):8685-91.

# Drug_Target_3_HGNC_ID:
HGNC:1043

# Drug_Target_3_HPRD_ID:
00205

# Drug_Target_3_ID:
798

# Drug_Target_3_Locus:
1q25-q31

# Drug_Target_3_Molecular_Weight:
10963

# Drug_Target_3_Name:
Osteocalcin

# Drug_Target_3_Number_of_Residues:
100

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00594	Gla

# Drug_Target_3_Protein_Sequence:
>Osteocalcin precursor
MRALTLLALLALAALCIAGQAGAKPSGAESSKGAAFVSKQEGSEVVKRPRRYLYQWLGAP
VPYPDPLEPRREVCELNPDCDELADHIGFQEAYRRFYGPV

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
1-23

# Drug_Target_3_Specific_Function:
Constitutes 1-2% of the total bone protein. It binds strongly to apatite and calcium

# Drug_Target_3_SwissProt_ID:
P02818

# Drug_Target_3_SwissProt_Name:
OSTCN_HUMAN

# Drug_Target_3_Synonyms:
BGP
Bone Gla-protein
Gamma-carboxyglutamic acid-containing protein
Osteocalcin precursor

# Drug_Target_3_Theoretical_pI:
7.18

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Not Available

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
12776254	Bockman R: The effects of gallium nitrate on bone resorption. Semin Oncol. 2003 Apr;30(2 Suppl 5):5-12.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
Not Available

# Drug_Target_4_GenBank_ID_Protein:
Not Available

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
Not Available

# Drug_Target_4_Gene_Sequence:
Not Available

# Drug_Target_4_General_Function:
Hydroxylapatite is the main mineral component of bone. Carbonated-calcium deficient hydroxyapatite is the main mineral of which dental enamel and dentin are comprised.

# Drug_Target_4_General_References:
Not Available

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
930

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
502.311

# Drug_Target_4_Name:
Hydroxyapatite

# Drug_Target_4_Number_of_Residues:
0

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
Not Available

# Drug_Target_4_Protein_Sequence:
Not Available

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
Not Available

# Drug_Target_4_Specific_Function:
Not Available

# Drug_Target_4_SwissProt_ID:
Not Available

# Drug_Target_4_SwissProt_Name:
Not Available

# Drug_Target_4_Synonyms:
Not Available

# Drug_Target_4_Theoretical_pI:
Not Available

# Drug_Target_4_Transmembrane_Regions:
Not Available

# Drug_Target_5_Cellular_Location:
Cytoplasmic

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
12776257	Straus DJ: Gallium nitrate in the treatment of lymphoma. Semin Oncol. 2003 Apr;30(2 Suppl 5):25-33.
15651176	Chitambar CR: Apoptotic mechanisms of gallium nitrate: basic and clinical investigations. Oncology (Williston Park). 2004 Nov;18(13 Suppl 10):39-44.
8467506	Berggren MM, Burns LA, Abraham RT, Powis G: Inhibition of protein tyrosine phosphatase by the antitumor agent gallium nitrate. Cancer Res. 1993 Apr 15;53(8):1862-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
AF164202

# Drug_Target_5_GenBank_ID_Protein:
Not Available

# Drug_Target_5_GeneCard_ID:
Not Available

# Drug_Target_5_Gene_Name:
PPI

# Drug_Target_5_Gene_Sequence:
>1086 bp
ATGAATAAAATTTATTGCCTTGCAGTACTGAGTCTAACGCTGCTGAGCCCACTTGCACTT
GCCAATACTGCAACTGAGTTTGATGGCCCTTACGTGATAACACCGATATCTGGTCAAAGC
ACGGCTTACTGGATCTGTGACAATAGACTCAAAACGACCTCGATAGAAAAGCTGCAAGTA
AATCGACCCGAGCATTGTGGGGATTTACCCGAGACTAAGCTCTCAAGCGAGATTAAGCAG
ATCATGCCTGACACTTACTTAGGTATTAAAAAGGTGGTCGCGTTAAGTGATGTACACGGC
CAGTATGACGTTCTGCTGACTCTGCTTAAAAAGCAAAAGATTATTGATAGTGATGGAAAT
TGGGCCTTCGGCGAGGGGCATATGGTGATGACGGGGGATATCTTTGACCGCGGCCATCAA
GTCAATGAAGTGCTGTGGTTTATGTATCAGCTCGACCAACAAGCACGAGACGCTGGCGGC
ATGGTACATCTATTAATGGGCAATCATGAACAGATGGTACTCGGCGGTGACTTGCGCTAT
GTACACCAGCGTTATGATATAGCCACAACCCTCATTAACCGCCCCTATAACAAGCTCTAC
GGCGCAGATACTGAAATAGGTCAGTGGTTAAGAAGTAAGAACACCATTATCAAGATCAAC
GATGTGCTGTATATGCATGGTGGGATCAGCAGCGAATGGATCAGTCGAGAGCTAACCTTA
GACAAAGCGAATGCACTGTATCGAGCTAATGTGGATGCGTCGAAAAAATCACTAAAGGCG
GATGACTTACTCAATTTCCTTTTTTTTGGAAACGGACCAACTTGGTATCGAGGCTACTTT
TCAGAAACATTTACCGAAGCTGAACTGGATACCATTTTACAACACTTTAACGTTAATCAT
ATCGTGGTCGGACACACCTCCCAAGAACGGGTCTTAGGTCTATTCCACAACAAAGTCATT
GCCGTCGATAGCAGCATAAAAGTCGGTAAATCAGGTGAACTGCTATTACTGGAAAATAAC
CGGCTTATACGCGGGTTATATGACGGAACACGTGAAACACTGCAGGAAAATAGCCTTAAT
CAATAA

# Drug_Target_5_General_Function:
Involved in hydrolase activity

# Drug_Target_5_General_References:
10731677	Tsuruta H, Aizono Y: Cloning of phosphatase I gene from a psychrophile, Shewanella sp., and some properties of the recombinant enzyme. J Biochem. 2000 Jan;127(1):143-9.

# Drug_Target_5_HGNC_ID:
Not Available

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
5142

# Drug_Target_5_Locus:
Not Available

# Drug_Target_5_Molecular_Weight:
40815

# Drug_Target_5_Name:
Protein-tyrosine-phosphatase

# Drug_Target_5_Number_of_Residues:
361

# Drug_Target_5_PDB_ID:
1V73

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00149	Metallophos

# Drug_Target_5_Protein_Sequence:
>Protein-tyrosine-phosphatase
MNKIYCLAVLSLTLLSPLALANTATEFDGPYVITPISGQSTAYWICDNRLKTTSIEKLQV
NRPEHCGDLPETKLSSEIKQIMPDTYLGIKKVVALSDVHGQYDVLLTLLKKQKIIDSDGN
WAFGEGHMVMTGDIFDRGHQVNEVLWFMYQLDQQARDAGGMVHLLMGNHEQMVLGGDLRY
VHQRYDIATTLINRPYNKLYGADTEIGQWLRSKNTIIKINDVLYMHGGISSEWISRELTL
DKANALYRANVDASKKSLKADDLLNFLFFGNGPTWYRGYFSETFTEAELDTILQHFNVNH
IVVGHTSQERVLGLFHNKVIAVDSSIKVGKSGELLLLENNRLIRGLYDGTRETLQENSLN
Q

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Not Available

# Drug_Target_5_SwissProt_ID:
Q9S427

# Drug_Target_5_SwissProt_Name:
Q9S427_9GAMM

# Drug_Target_5_Synonyms:
EC 3.1.3.48

# Drug_Target_5_Theoretical_pI:
6.38

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Secreted protein. Note=The lack of a specific hydrophobic segment in the precursor sequence suggests

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
16122880	Eby G: Elimination of arthritis pain and inflammation for over 2 years with a single 90 min, topical 14% gallium nitrate treatment: case reports and review of actions of gallium III. Med Hypotheses. 2005;65(6):1136-41. Epub 2005 Aug 24.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
IL1B

# Drug_Target_6_GenBank_ID_Gene:
K02770

# Drug_Target_6_GenBank_ID_Protein:
307043

# Drug_Target_6_GeneCard_ID:
IL1B

# Drug_Target_6_Gene_Name:
IL1B

# Drug_Target_6_Gene_Sequence:
>810 bp
ATGGCAGAAGTACCTAAGCTCGCCAGTGAAATGATGGCTTATTACAGTGGCAATGAGGAT
GACTTGTTCTTTGAAGCTGATGGCCCTAAACAGATGAAGTGCTCCTTCCAGGACCTGGAC
CTCTGCCCTCTGGATGGCGGCATCCAGCTACGAATCTCCGACCACCACTACAGCAAGGGC
TTCAGGCAGGCCGCGTCAGTTGTTGTGGCCATGGACAAGCTGAGGAAGATGCTGGTTCCC
TGCCCACAGACCTTCCAGGAGAATGACCTGAGCACCTTCTTTCCCTTCATCTTTGAAGAA
GAACCTATCTTCTTCGACACATGGGATAACGAGGCTTATGTGCACGATGCACCTGTACGA
TCACTGAACTGCACGCTCCGGGACTCACAGCAAAAAAGCTTGGTGATGTCTGGTCCATAT
GAACTGAAAGCTCTCCACCTCCAGGGACAGGATATGGAGCAACAAGTGGTGTTCTCCATG
TCCTTTGTACAAGGAGAAGAAAGTAATGACAAAATACCTGTGGCCTTGGGCCTCAAGGAA
AAGAATCTGTACCTGTCCTGCGTGTTGAAAGATGATAAGCCCACTCTACAGCTGGAGAGT
GTAGATCCCAAAAATTACCCAAAGAAGAAGATGGAAAAGCGATTTGTCTTCAACAAGATA
GAAATCAATAACAAGCTGGAATTTGAGTCTGCCCAGTTCCCCAACTGGTACATCAGCACC
TCTCAAGCAGAAAACATGCCCGTCTTCCTGGGAGGGACCAAAGGCGGCCAGGATATAACT
GACTTCACCATGCAATTTGTGTCTTCCTAA

# Drug_Target_6_General_Function:
Involved in growth factor activity

# Drug_Target_6_General_References:
11991722	Nicklin MJ, Barton JL, Nguyen M, FitzGerald MG, Duff GW, Kornman K: A sequence-based map of the nine genes of the human interleukin-1 cluster. Genomics. 2002 May;79(5):718-25.
1837236	Nanduri VB, Hulmes JD, Pan YC, Kilian PL, Stern AS: The role of arginine residues in interleukin 1 receptor binding. Biochim Biophys Acta. 1991 Dec 11;1118(1):25-35.
1919436	Mizutani H, Schechter N, Lazarus G, Black RA, Kupper TS: Rapid and specific conversion of precursor interleukin 1 beta (IL-1 beta) to an active IL-1 species by human mast cell chymase. J Exp Med. 1991 Oct 1;174(4):821-5.
2001363	Clore GM, Wingfield PT, Gronenborn AM: High-resolution three-dimensional structure of interleukin 1 beta in solution by three- and four-dimensional nuclear magnetic resonance spectroscopy. Biochemistry. 1991 Mar 5;30(9):2315-23.
2372550	Driscoll PC, Gronenborn AM, Wingfield PT, Clore GM: Determination of the secondary structure and molecular topology of interleukin-1 beta by use of two- and three-dimensional heteronuclear 15N-1H NMR spectroscopy. Biochemistry. 1990 May 15;29(19):4668-82.
2585509	Finzel BC, Clancy LL, Holland DR, Muchmore SW, Watenpaugh KD, Einspahr HM: Crystal structure of recombinant human interleukin-1 beta at 2.0 A resolution. J Mol Biol. 1989 Oct 20;209(4):779-91.
2602367	Priestle JP, Schar HP, Grutter MG: Crystallographic refinement of interleukin 1 beta at 2.0 A resolution. Proc Natl Acad Sci U S A. 1989 Dec;86(24):9667-71.
2635664	Kotenko SV, Bulenkov MT, Veiko VP, Epishin SM, Lomakin IB: [Cloning of the cDNA coding for human prointerleukin-1 alpha and prointerleukin-1 beta] Dokl Akad Nauk SSSR. 1989;309(4):1005-8.
2954882	Bensi G, Raugei G, Palla E, Carinci V, Tornese Buonamassa D, Melli M: Human interleukin-1 beta gene. Gene. 1987;52(1):95-101.
2989698	March CJ, Mosley B, Larsen A, Cerretti DP, Braedt G, Price V, Gillis S, Henney CS, Kronheim SR, Grabstein K, et al.: Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature. 1985 Jun 20-26;315(6021):641-7.
3259176	Priestle JP, Schar HP, Grutter MG: Crystal structure of the cytokine interleukin-1 beta. EMBO J. 1988 Feb;7(2):339-43.
3281727	Zsebo KM, Wypych J, Yuschenkoff VN, Lu H, Hunt P, Dukes PP, Langley KE: Effects of hematopoietin-1 and interleukin 1 activities on early hematopoietic cells of the bone marrow. Blood. 1988 Apr;71(4):962-8.
3490654	Clark BD, Collins KL, Gandy MS, Webb AC, Auron PE: Genomic sequence for human prointerleukin 1 beta: possible evolution from a reverse transcribed prointerleukin 1 alpha gene. Nucleic Acids Res. 1986 Oct 24;14(20):7897-914.
3493774	Nishida T, Nishino N, Takano M, Kawai K, Bando K, Masui Y, Nakai S, Hirai Y: cDNA cloning of IL-1 alpha and IL-1 beta from mRNA of U937 cell line. Biochem Biophys Res Commun. 1987 Feb 27;143(1):345-52.
6083565	Auron PE, Webb AC, Rosenwasser LJ, Mucci SF, Rich A, Wolff SM, Dinarello CA: Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci U S A. 1984 Dec;81(24):7907-11.
9062193	Vigers GP, Anderson LJ, Caffes P, Brandhuber BJ: Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1beta. Nature. 1997 Mar 13;386(6621):190-4.

# Drug_Target_6_HGNC_ID:
HGNC:5992

# Drug_Target_6_HPRD_ID:
00985

# Drug_Target_6_ID:
1654

# Drug_Target_6_Locus:
2q14

# Drug_Target_6_Molecular_Weight:
30748

# Drug_Target_6_Name:
Interleukin-1 beta

# Drug_Target_6_Number_of_Residues:
269

# Drug_Target_6_PDB_ID:
9ILB

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF00340	IL1
PF02394	IL1_propep

# Drug_Target_6_Protein_Sequence:
>Interleukin-1 beta precursor
MAEVPELASEMMAYYSGNEDDLFFEADGPKQMKCSFQDLDLCPLDGGIQLRISDHHYSKG
FRQAASVVVAMDKLRKMLVPCPQTFQENDLSTFFPFIFEEEPIFFDTWDNEAYVHDAPVR
SLNCTLRDSQQKSLVMSGPYELKALHLQGQDMEQQVVFSMSFVQGEESNDKIPVALGLKE
KNLYLSCVLKDDKPTLQLESVDPKNYPKKKMEKRFVFNKIEINNKLEFESAQFPNWYIST
SQAENMPVFLGGTKGGQDITDFTMQFVSS

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
Produced by activated macrophages, IL-1 stimulates thymocyte proliferation by inducing IL-2 release, B-cell maturation and proliferation, and fibroblast growth factor activity. IL-1 proteins are involved in the inflammatory response, being identified as endogenous pyrogens, and are reported to stimulate the release of prostaglandin and collagenase from synovial cells

# Drug_Target_6_SwissProt_ID:
P01584

# Drug_Target_6_SwissProt_Name:
IL1B_HUMAN

# Drug_Target_6_Synonyms:
Catabolin
IL-1 beta
Interleukin-1 beta precursor

# Drug_Target_6_Theoretical_pI:
4.45

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Not Available

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
15651176	Chitambar CR: Apoptotic mechanisms of gallium nitrate: basic and clinical investigations. Oncology (Williston Park). 2004 Nov;18(13 Suppl 10):39-44.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
Not Available

# Drug_Target_7_GenBank_ID_Gene:
Not Available

# Drug_Target_7_GenBank_ID_Protein:
Not Available

# Drug_Target_7_GeneCard_ID:
Not Available

# Drug_Target_7_Gene_Name:
Not Available

# Drug_Target_7_Gene_Sequence:
Not Available

# Drug_Target_7_General_Function:
Not Available

# Drug_Target_7_General_References:
Not Available

# Drug_Target_7_HGNC_ID:
Not Available

# Drug_Target_7_HPRD_ID:
Not Available

# Drug_Target_7_ID:
7209

# Drug_Target_7_Locus:
Not Available

# Drug_Target_7_Molecular_Weight:
Not Available

# Drug_Target_7_Name:
Transferrin Receptor Protein

# Drug_Target_7_Number_of_Residues:
0

# Drug_Target_7_PDB_ID:
Not Available

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
Not Available

# Drug_Target_7_Protein_Sequence:
Not Available

# Drug_Target_7_Reaction:
Not Available

# Drug_Target_7_Signals:
Not Available

# Drug_Target_7_Specific_Function:
Not Available

# Drug_Target_7_SwissProt_ID:
Not Available

# Drug_Target_7_SwissProt_Name:
Not Available

# Drug_Target_7_Synonyms:
Not Available

# Drug_Target_7_Theoretical_pI:
Not Available

# Drug_Target_7_Transmembrane_Regions:
Not Available

#END_DRUGCARD DB05260
